Cargando…

Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial

BACKGROUND: To investigate the effects of intraoperative application of dexmedetomidine (Dex) on early gastrointestinal motility after laparoscopic resection of colorectal cancer. METHODS: In this prospective, randomized double-blind investigation, 60 patients who underwent laparoscopic resection of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chaojin, Huang, Pinjie, Lai, Lifei, Luo, Chenfang, Ge, Mian, Hei, Ziqing, Zhu, Qianqian, Zhou, Shaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265791/
https://www.ncbi.nlm.nih.gov/pubmed/27442674
http://dx.doi.org/10.1097/MD.0000000000004295
_version_ 1782500337209311232
author Chen, Chaojin
Huang, Pinjie
Lai, Lifei
Luo, Chenfang
Ge, Mian
Hei, Ziqing
Zhu, Qianqian
Zhou, Shaoli
author_facet Chen, Chaojin
Huang, Pinjie
Lai, Lifei
Luo, Chenfang
Ge, Mian
Hei, Ziqing
Zhu, Qianqian
Zhou, Shaoli
author_sort Chen, Chaojin
collection PubMed
description BACKGROUND: To investigate the effects of intraoperative application of dexmedetomidine (Dex) on early gastrointestinal motility after laparoscopic resection of colorectal cancer. METHODS: In this prospective, randomized double-blind investigation, 60 patients who underwent laparoscopic resection of colorectal cancer were randomly allocated to receive Dex (DEX group, n = 30) or saline (CON group, n = 30). In the DEX group, Dex was loaded (1 μg/kg) before anesthesia induction and was infused (0.3 μg/kg/h) during surgery. Time to postoperative first flatus (FFL) and first feces (FFE), and time to regular diet were recorded. Serum diamine oxidase (DAO) activity and intestinal fatty acid-binding protein (I-FABP) were detected. RESULTS: Both the time to the FFL (44.41 ± 4.51 hours vs 61.03 ± 5.16 hours, P = 0.02) and the time to the FFE (60.67 ± 4.94 hours vs 82.50 ± 6.88 hours, P = 0.014) were significantly shorter in the DEX group than the CON group. Furthermore, the time to regular diet of the DEX group was shorter than that of the CON group (76.15 ± 4.11 hours vs 91.50 ± 5.70 hours, P = 0.037). Both DAO and I-FABP increased significantly from beginning of surgery to postoperative day 1 in the CON group (2.49 ± 0.41 ng/mL vs 4.48 ± 0.94 ng/mL for DAO, P = 0.028, 1.32 ± 0.09 ng/mL vs 2.17 ± 0.12 ng/mL for I-FABP, P = 0.045, respectively), whereas no significant change was observed in the DEX group. Furthermore, patients in the DEX group had stable hemodynamics and shorter hospital stay than those in the CON group. CONCLUSION: Dex administration intraoperatively benefits recovery of gastrointestinal motility function after laparoscopic resection of colorectal cancer with stable hemodynamics during surgery though further studies are needed to explore the mechanisms of Dex on gastrointestinal motility.
format Online
Article
Text
id pubmed-5265791
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52657912017-02-03 Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial Chen, Chaojin Huang, Pinjie Lai, Lifei Luo, Chenfang Ge, Mian Hei, Ziqing Zhu, Qianqian Zhou, Shaoli Medicine (Baltimore) 4500 BACKGROUND: To investigate the effects of intraoperative application of dexmedetomidine (Dex) on early gastrointestinal motility after laparoscopic resection of colorectal cancer. METHODS: In this prospective, randomized double-blind investigation, 60 patients who underwent laparoscopic resection of colorectal cancer were randomly allocated to receive Dex (DEX group, n = 30) or saline (CON group, n = 30). In the DEX group, Dex was loaded (1 μg/kg) before anesthesia induction and was infused (0.3 μg/kg/h) during surgery. Time to postoperative first flatus (FFL) and first feces (FFE), and time to regular diet were recorded. Serum diamine oxidase (DAO) activity and intestinal fatty acid-binding protein (I-FABP) were detected. RESULTS: Both the time to the FFL (44.41 ± 4.51 hours vs 61.03 ± 5.16 hours, P = 0.02) and the time to the FFE (60.67 ± 4.94 hours vs 82.50 ± 6.88 hours, P = 0.014) were significantly shorter in the DEX group than the CON group. Furthermore, the time to regular diet of the DEX group was shorter than that of the CON group (76.15 ± 4.11 hours vs 91.50 ± 5.70 hours, P = 0.037). Both DAO and I-FABP increased significantly from beginning of surgery to postoperative day 1 in the CON group (2.49 ± 0.41 ng/mL vs 4.48 ± 0.94 ng/mL for DAO, P = 0.028, 1.32 ± 0.09 ng/mL vs 2.17 ± 0.12 ng/mL for I-FABP, P = 0.045, respectively), whereas no significant change was observed in the DEX group. Furthermore, patients in the DEX group had stable hemodynamics and shorter hospital stay than those in the CON group. CONCLUSION: Dex administration intraoperatively benefits recovery of gastrointestinal motility function after laparoscopic resection of colorectal cancer with stable hemodynamics during surgery though further studies are needed to explore the mechanisms of Dex on gastrointestinal motility. Wolters Kluwer Health 2016-07-22 /pmc/articles/PMC5265791/ /pubmed/27442674 http://dx.doi.org/10.1097/MD.0000000000004295 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 4500
Chen, Chaojin
Huang, Pinjie
Lai, Lifei
Luo, Chenfang
Ge, Mian
Hei, Ziqing
Zhu, Qianqian
Zhou, Shaoli
Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial
title Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial
title_full Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial
title_fullStr Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial
title_full_unstemmed Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial
title_short Dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: A randomized clinical trial
title_sort dexmedetomidine improves gastrointestinal motility after laparoscopic resection of colorectal cancer: a randomized clinical trial
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265791/
https://www.ncbi.nlm.nih.gov/pubmed/27442674
http://dx.doi.org/10.1097/MD.0000000000004295
work_keys_str_mv AT chenchaojin dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT huangpinjie dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT lailifei dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT luochenfang dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT gemian dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT heiziqing dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT zhuqianqian dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial
AT zhoushaoli dexmedetomidineimprovesgastrointestinalmotilityafterlaparoscopicresectionofcolorectalcancerarandomizedclinicaltrial